View Item 

Show simple item record

First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non‐interventional study

dc.contributor.authorLencioni, R.en_US
dc.contributor.authorKudo, M.en_US
dc.contributor.authorYe, S.‐l.en_US
dc.contributor.authorBronowicki, J.‐p.en_US
dc.contributor.authorChen, X.‐p.en_US
dc.contributor.authorDagher, L.en_US
dc.contributor.authorFuruse, J.en_US
dc.contributor.authorGeschwind, J. F.en_US
dc.contributor.authorde Guevara, L. L.en_US
dc.contributor.authorPapandreou, C.en_US
dc.contributor.authorSanyal, A. J.en_US
dc.contributor.authorTakayama, T.en_US
dc.contributor.authorYoon, S. K.en_US
dc.contributor.authorNakajima, K.en_US
dc.contributor.authorCihon, F.en_US
dc.contributor.authorHeldner, S.en_US
dc.contributor.authorMarrero, J. A.en_US
dc.date.accessioned2012-07-12T17:24:08Z
dc.date.available2013-09-03T15:38:27Zen_US
dc.date.issued2012-07en_US
dc.identifier.citationLencioni, R.; Kudo, M.; Ye, S.‐l. ; Bronowicki, J.‐p. ; Chen, X.‐p. ; Dagher, L.; Furuse, J.; Geschwind, J. F.; de Guevara, L. L.; Papandreou, C.; Sanyal, A. J.; Takayama, T.; Yoon, S. K.; Nakajima, K.; Cihon, F.; Heldner, S.; Marrero, J. A. (2012). "First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) nonâ interventional study." International Journal of Clinical Practice 66(7). <http://hdl.handle.net/2027.42/92068>en_US
dc.identifier.issn1368-5031en_US
dc.identifier.issn1742-1241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/92068
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleFirst interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non‐interventional studyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Medicine, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDivision of Diagnostic Imaging and Intervention, Pisa University Hospital and School of Medicine, Pisa, Italyen_US
dc.contributor.affiliationotherDepartment of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japanen_US
dc.contributor.affiliationotherLiver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, Chinaen_US
dc.contributor.affiliationotherDepartment of Gastroenterology and Hepatology, INSERM U954, University Hospital of Nancy, University Henri Poincaré, Vandœuvre‐lès‐Nancy, Franceen_US
dc.contributor.affiliationotherHepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Chinaen_US
dc.contributor.affiliationotherPoliclínica Metropolitana, Caracas, Venezuelaen_US
dc.contributor.affiliationotherKyorin University, Mitaka, Tokyo, Japanen_US
dc.contributor.affiliationotherVascular and Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USAen_US
dc.contributor.affiliationotherHospital Angeles Clínica Londres, Mexico City, Mexicoen_US
dc.contributor.affiliationotherUniversity Hospital of Larissa, Larissa, Greeceen_US
dc.contributor.affiliationotherVirginia Commonwealth University Medical Center, Richmond, VA, USAen_US
dc.contributor.affiliationotherDepartment of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japanen_US
dc.contributor.affiliationotherThe Catholic University of Korea, Seoul, Koreaen_US
dc.contributor.affiliationotherGlobal Medical Affairs, Bayer HealthCare Pharmaceuticals, Montville, NJ, USAen_US
dc.contributor.affiliationotherClinical Statistics, Bayer HealthCare Pharmaceuticals, Montville, NJ, USAen_US
dc.contributor.affiliationotherGlobal Medical Affairs and Pharmacovigilance, Bayer HealthCare Pharmaceuticals, Berlin, Germanyen_US
dc.identifier.pmid22698419en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/92068/1/j.1742-1241.2012.02940.x.pdf
dc.identifier.doi10.1111/j.1742-1241.2012.02940.xen_US
dc.identifier.sourceInternational Journal of Clinical Practiceen_US
dc.identifier.citedreferenceThomas MB, Jaffe D, Choti MM et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28: 3994 – 4005.en_US
dc.identifier.citedreferenceVenook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 ( Suppl 4 ): 5 – 13.en_US
dc.identifier.citedreferenceJemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69 – 90.en_US
dc.identifier.citedreferenceFuruse J, Ishii H, Nakachi K et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159 – 65.en_US
dc.identifier.citedreferenceAbou‐Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293 – 300.en_US
dc.identifier.citedreferenceLord R, Suddle A, Ross PJ. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. Int J Clin Pract 2011; 65: 182 – 8.en_US
dc.identifier.citedreferenceSanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010; 15 ( Suppl 4 ): 14 – 22.en_US
dc.identifier.citedreferenceTandon P, Garcia‐Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29: 502 – 10.en_US
dc.identifier.citedreferenceYau T, Chan P, Ng KK et al. Phase 2 open‐label study of single‐agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B‐endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428 – 36.en_US
dc.identifier.citedreferenceFarinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89: 2266 – 73.en_US
dc.identifier.citedreferenceLencioni R. Loco‐regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762 – 73.en_US
dc.identifier.citedreferenceLencioni R, Marrero J, Venook A, Ye SY, Kudo M. Design and rationale for the non‐interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study. Int J Clin Pract 2010; 64: 1034 – 41.en_US
dc.identifier.citedreferenceOzenne V, Paradis V, Pernot S et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010; 22: 1106 – 10.en_US
dc.identifier.citedreferenceLlovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378 – 90.en_US
dc.identifier.citedreferenceCheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia‐Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double‐blind, placebo‐controlled trial. Lancet Oncol 2009; 10: 25 – 34.en_US
dc.identifier.citedreferenceBruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020 – 2.en_US
dc.identifier.citedreferenceGish RG, Marrero JA, Benson AB. A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2010; 6 ( Suppl 3 ): 1 – 16.en_US
dc.identifier.citedreferenceLopez PM, Villanueva A, Llovet JM. Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535 – 47.en_US
dc.identifier.citedreferenceNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: hepatobiliary cancers (Version 2.2012). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. (accessed April 2011).en_US
dc.identifier.citedreferenceEl‐Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557 – 76.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1742-1241.2012.02940.x.pdf
Size:
202.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.